{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:00:23Z","timestamp":1785265223156,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.cllc.2024.12.001","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T02:39:37Z","timestamp":1733366377000},"page":"165-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8592-9892","authenticated-orcid":false,"given":"Jennifer A.","family":"Marks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeil","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua E.","family":"Reuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Barbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina C.","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Riely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen V.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0191-8684","authenticated-orcid":false,"given":"Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cllc.2024.12.001_bib0001","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jtho.2022.01.021","article-title":"Thymic carcinomas\u2014a concise multidisciplinary update on recent developments from the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group","volume":"17","author":"Roden","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.12.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102014","article-title":"Thymic epithelial tumors: from biology to treatment","volume":"86","author":"Conforti","year":"2020","journal-title":"Cancer treatm Rev"},{"issue":"3","key":"10.1016\/j.cllc.2024.12.001_bib0003","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"10.1016\/j.cllc.2024.12.001_bib0004","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/cge.14285","article-title":"Genomic characterization of thymic epithelial tumors reveals critical genes underlying tumorigenesis and poor prognosis","volume":"103","author":"Tan","year":"2023","journal-title":"Clinical Genetics"},{"issue":"3-4","key":"10.1016\/j.cllc.2024.12.001_bib0005","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications","volume":"6","author":"Shvartsur","year":"2015","journal-title":"Genes Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2024.12.001_bib0006","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/onc.2012.36","article-title":"Upregulation of Trop-2 quantitatively stimulates human cancer growth","volume":"32","author":"Trerotola","year":"2013","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.cllc.2024.12.001_bib0007","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1158\/1538-7445.AM2023-2171","article-title":"A multivariate biomarker predicts sacituzumab govitecan-hziy response in solid tumors","volume":"83","author":"Khazanov","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2024.12.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107324","article-title":"High levels of expression of Trop-2 in thymic epithelial tumors","volume":"184","author":"Yeung","year":"2023","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2024.12.001_bib0009","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.cllc.2024.01.001","article-title":"Trop-2 expression and its impact on survival in thymic sepithelial tumors: brief report","volume":"25","author":"Ardeshir-Larijani","year":"2024","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"10.1016\/j.cllc.2024.12.001_bib0010","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s11912-022-01334-9","article-title":"Antibody\u2013Drug conjugates in non-small cell lung cancer: emergence of a novel therapeutic class","volume":"24","author":"Marks","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.cllc.2024.12.001_sbref0011","series-title":"Trodelvy (sacituzumab govitecan-hziy) [package insert]","year":"2023"},{"issue":"8","key":"10.1016\/j.cllc.2024.12.001_bib0012","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.cllc.2024.12.001_bib0013","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan-hziy (IMMU-132), an anti-trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2024.12.001_bib0014","series-title":"Multivariate Biomarker Predicts Sacituzumab Govitecan Response in Solid Tumors","author":"Khazanov","year":"2023"},{"issue":"1","key":"10.1016\/j.cllc.2024.12.001_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Controlled clinical trials"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042400264X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042400264X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T11:12:04Z","timestamp":1749294724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573042400264X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S152573042400264X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2024.12.001","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2024.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}